Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleselumab for rFSGS prevention in kidney transplant
NCT02921789Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2017
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in focal segmental glomerulosclerosis (FSGS) comparing Standard of Care (SOC) Regimen with Bleselumab Regimen (2 arms). Primary endpoint: Percentage of Participants With Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss or Lost to Follow-up at 3 months. Started May 2017; status: completed.
02
Drugs
bleselumab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT02921789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921789.